,Drug_1,drug2,Level_of_interaction,Quality_of_interaction,Summary,Description
0,Panobinostat,Acarbose,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and by the microbial flora. Panobinostat is unlikely to interfere with this metabolic pathway.",See Summary
1,Panobinostat,Acenocoumarol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Acenocoumarol is mainly metabolised by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Panobinostat does not inhibit or induce CYPs 2C9, 1A2 or 2C19. However, panobinostat in combination with acenocoumarol increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
2,Panobinostat,Acetylsalicylic acid (Aspirin),"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Aspirin is rapidly deacetylated to form salicylic acid and then further metabolised by glucuronidation (by several UGTs, major UGT1A6). Panobinostat does not inhibit or induce UGTs. However, panobinostat in combination with acetylsalicylic acid increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
3,Panobinostat,Agomelatine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly via CYP1A2 (90%), with a small proportion metabolised by CYP2C9 and CYP2C19 (10%). Panobinostat does not inhibit or induce CYPs 1A2, 2C9 or 2C19.",See Summary
4,Panobinostat,Alendronic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Alendronate is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, alendronate should be separated from food or other medicinal products and patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.",See Summary
5,Panobinostat,Alfentanil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes extensive CYP3A4 metabolism. Panobinostat is an inhibitor of CYP3A4 in vitro. However, a clinically relevant effect on alfentanil exposure is not expected in vivo. ",See Summary
6,Panobinostat,Alfuzosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfuzosin is metabolised by CYP3A. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on alfuzosin exposure is not expected in vivo.,See Summary
7,Panobinostat,Aliskiren,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolised and is mainly excreted unchanged in faeces. Aliskiren is also a substrate of P-gp. Panobinostat does not interact with this elimination pathway.,See Summary
8,Panobinostat,Allopurinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Panobinostat does not interact with this metabolic pathway.,See Summary
9,Panobinostat,Alosetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that alosetron is metabolised by CYPs 2C9, 3A4 and 1A2. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on alosetron exposure is not expected in vivo.",See Summary
10,Panobinostat,Alprazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on alprazolam exposure is not expected in vivo.,See Summary
11,Panobinostat,Aluminium hydroxide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aluminium hydroxide is not metabolised. Panobinostat does not interact with this pathway. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with aluminium hydroxide is not expected.",See Summary
12,Panobinostat,Ambrisentan,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ambrisentan is metabolised by glucuronidation via UGTs 1A3, 1A9 and 2B7 and to a lesser extent by CYP3A4 and CYP2C19. Ambrisentan is also a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on ambrisentan exposure is not expected in vivo.",See Summary
13,Panobinostat,Amikacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amikacin is eliminated by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
14,Panobinostat,Amiloride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged in the kidney. In vitro data indicate that amiloride is a substrate of OCT2. Panobinostat is an inhibitor of OCT2 in vitro but a clinically relevant effect on amiloride exposure is not expected in vivo.,See Summary
15,Panobinostat,Amiodarone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Amiodarone is metabolised by CYP3A4 and CYP2C8. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on amiodarone exposure is not expected in vivo. However, the major metabolite of amiodarone, desethylamiodarone, is an inhibitor of CYPs 3A4 (weak), 2C9 (moderate), 2D6 (moderate), 2C19 (weak), 1A1 (strong) and 2B6 (moderate). Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Due to the long half-life of amiodarone, interactions can be observed for several months after discontinuation of amiodarone. Furthermore, panobinostat and amiodarone may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
16,Panobinostat,Amisulpride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolised and is primarily eliminated renally (possibly via OCT). Panobinostat is an inhibitor of OCT1 and OCT2 in vitro but a clinically relevant effect on amisulpride exposure is not expected in vivo. ,See Summary
17,Panobinostat,Amitriptyline,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19, with a small proportion metabolised by CYPs 3A4, 1A2 and 2C9. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of amitriptyline. Monitor closely for amitriptyline toxicity. Furthermore, panobinostat and amitriptyline may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
18,Panobinostat,Amlodipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on amlodipine exposure is not expected in vivo.,See Summary
19,Panobinostat,Amoxicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on amoxicillin exposure is not expected in vivo.,See Summary
20,Panobinostat,Amphotericin B,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Amphotericin B is not appreciably metabolised but is eliminated to a large extent in the bile. Panobinostat does not interfere with this elimination pathway. However, the European SPC for amphotericin states that concomitant use of amphotericin B and antineoplastic agents can increase the risk of renal toxicity, bronchospasm and hypotension, and so monitoring may be required.",See Summary
21,Panobinostat,Ampicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. About 20-40% of an oral dose may be excreted unchanged in the urine in 6 hours. After parenteral use about 60-80% is excreted in the urine within 6 hours. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
22,Panobinostat,Anidulafungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperatures. Panobinostat is unlikely to interfere with this metabolic pathway.,See Summary
23,Panobinostat,Antacids,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Antacids are not metabolised by CYPs. Panobinostat is unlikely to interfere with this metabolic pathway. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with antacids is not expected.",See Summary
24,Panobinostat,Apixaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Apixaban is a substrate of P-gp and BCRP, and is metabolised by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8, 2C9 and 2C19. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on apixaban exposure is not expected in vivo. However, panobinostat in combination with apixaban increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
25,Panobinostat,Aprepitant,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on aprepitant exposure is not expected in vivo. However, during treatment aprepitant is a moderate inhibitor of CYP3A4. After treatment, aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Concentrations of panobinostat may both increase and decrease due to inhibition and induction of CYP3A4 respectively. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required during the three days of coadministration. Decreased exposure due to CYP3A4 induction after aprepitant treatment is considered not to be clinically relevant.",See Summary
26,Panobinostat,Aripiprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Aripiprazole is metabolised by CYP3A4 and CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase aripiprazole exposure. Therefore, care should be taken when aripiprazole is coadministered with panobinostat. Monitoring for aripiprazole toxicity may be required.",See Summary
27,Panobinostat,Asenapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolised by glucuronidation (UGT1A4) and oxidative metabolism (CYPs 1A2 (major), 3A4 (minor) and 2D6 (minor)). Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak). However, since CYP2D6 and CYP3A4 are minor pathways, a clinically relevant effect on asenapine exposure is not expected.",See Summary
28,Panobinostat,Astemizole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Astemizole is metabolised by CYPs 2D6, 2J2 and 3A4. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of astemizole. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, monitor closely for astemizole toxicity. Furthermore, panobinostat and astemizole may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
29,Panobinostat,Atenolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated unchanged in the kidney, predominantly by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.",See Summary
30,Panobinostat,Atorvastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atorvastatin is metabolised by CYP3A4 and is a substrate of P-gp and OATP1B1. Panobinostat is an inhibitor of CYP3A4 and OATP1B1 in vitro but a clinically relevant effect on atorvastatin exposure is not expected in vivo.,See Summary
31,Panobinostat,Azathioprine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolised analogously to natural purines. Panobinostat does not interact with this metabolic pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
32,Panobinostat,Azithromycin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion; animal data suggest this may occur via P-gp and MRP2. Panobinostat does not inhibit or induce P-gp or MRP2. Azithromycin is also an inhibitor of P-gp and may increase concentrations of panobinostat. The clinical relevance of P-gp inhibition by azithromycin is unknown but a clinically significant effect on panobinostat exposure is not expected. However, panobinostat and azithromycin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG. ",See Summary
33,Panobinostat,Beclometasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450, but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate. Panobinostat does not interact with this metabolic pathway.",See Summary
34,Panobinostat,Bedaquiline,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bedaquiline is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on bedaquiline exposure is not expected in vivo. However, panobinostat and bedaquiline may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
35,Panobinostat,Bendroflumethiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on bendroflumethiazide exposure is not expected in vivo. In vitro data indicate that bendroflumethiazide inhibits these renal transporters but a clinically significant interaction is unlikely in the range of observed clinical concentrations. ,See Summary
36,Panobinostat,Bepridil,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Bepridil is metabolised by CYP2D6 (major) and CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on bepridil exposure is not expected in vivo. Panobinostat is also a weak inhibitor of CYP2D6 and may increase concentrations of bepridil. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with bepridil. Therefore, coadministration should be approached with caution. If coadministration is necessary, monitor closely for bepridil toxicity. Furthermore, panobinostat and bepridil may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
37,Panobinostat,Betamethasone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betamethasone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on betamethasone exposure is not expected in vivo.,See Summary
38,Panobinostat,Bezafibrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Half of a bezafibrate dose is eliminated unchanged in the urine. In vitro data suggest that bezafibrate inhibits the renal transporter OAT1. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
39,Panobinostat,Bisacodyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. Panobinostat does not interact with this pathway.,See Summary
40,Panobinostat,Bisoprolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolised by CYP3A4 and CYP2D6, and partly eliminated unchanged in the urine. Furthermore, panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) but a clinically relevant effect on bisoprolol exposure is not expected.",See Summary
41,Panobinostat,Bosentan,"
Potential Interaction
","
Low
","Coadministration has not been studied but should be approached with caution. Bosentan is a substrate of CYP3A4 and CYP2C9. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on bosentan exposure is not expected in vivo. However, bosentan is a weak inducer of CYP3A4 and CYP2C9. Concentrations of panobinostat may decrease due to CYP3A4 induction. The clinical relevance of this interaction is unknown. Decreased exposure may lead to decreased efficacy. Therefore, coadministration should be approached with caution. Monitor closely for panobinostat efficacy. Monitor panobinostat plasma concentrations, if available.",See Summary
42,Panobinostat,Bromazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may also play a role. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro). However, since multiple CYP enzymes are involved and bromazepam has a broad therapeutic index, a clinically relevant interaction is not expected.",See Summary
43,Panobinostat,Budesonide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Budesonide is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on budesonide exposure is not expected in vivo.,See Summary
44,Panobinostat,Buprenorphine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on buprenorphine exposure is not expected in vivo.,See Summary
45,Panobinostat,Bupropion,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolised by CYP2B6. Panobinostat does not inhibit or induce CYP2B6.,See Summary
46,Panobinostat,Buspirone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on buspirone exposure is not expected in vivo.,See Summary
47,Panobinostat,Calcium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat. Panobinostat does not interact with this elimination pathway.",See Summary
48,Panobinostat,Candesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Candesartan is mainly eliminated unchanged via urine and bile. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
49,Panobinostat,Capreomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
50,Panobinostat,Captopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1. Panobinostat does not inhibit or induce OAT1.,See Summary
51,Panobinostat,Carbamazepine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Carbamazepine is primarily metabolised by CYP3A4 and to a lesser extent by CYP2C8. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on carbamazepine exposure is not expected in vivo. Furthermore, carbamazepine is an inducer of CYPs 2C8 (strong), 2C9 (strong), 3A4 (strong), 1A2 (weak), 2B6 and UGT1A1. Concentrations of panobinostat may decrease due to strong induction of CYP3A4. The clinical relevance of this interaction is unknown as interaction studies with CYP3A inducers have not been performed. In a PBPK simulation, coadministration of rifampicin, a strong CYP3A4 inducer, and panobinostat decreased panobinostat exposure by ~ 60%. A similar effect may occur with carbamazepine. A decrease in exposure may lead to a decreased efficacy. Therefore, coadministration should be avoided.",See Summary
52,Panobinostat,Carvedilol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additional metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of carvedilol. Therefore, care should be taken if carvedilol is coadministered with panobinostat. Monitoring for blood pressure may be required.",See Summary
53,Panobinostat,Caspofungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non-CYP mediated pathway. Panobinostat is unlikely to interfere with this metabolic pathway.,See Summary
54,Panobinostat,Cefalexin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged renally by glomerular filtration and tubular secretion via OAT1 and MATE1. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
55,Panobinostat,Cefazolin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on cefazolin exposure is not expected in vivo.",See Summary
56,Panobinostat,Cefixime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefixime is renally excreted predominantly by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
57,Panobinostat,Cefotaxime,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolised by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. In vitro studies indicate that OAT3 participates in the renal elimination of cefotaxime. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on cefotaxime exposure is not expected in vivo.",See Summary
58,Panobinostat,Ceftazidime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftazidime is excreted predominantly by renal glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
59,Panobinostat,Ceftriaxone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. Panobinostat is unlikely to interfere with this elimination pathway.",See Summary
60,Panobinostat,Celecoxib,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is primarily metabolised by CYP2C9. Panobinostat does not inhibit or induce CYP2C9.,See Summary
61,Panobinostat,Cetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Panobinostat is unlikely to interfere with this elimination pathway. In vitro data indicate that cetirizine is also an inhibitor of OCT2. Panobinostat is not transported by OCT2. ,See Summary
62,Panobinostat,Chloramphenicol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Chloramphenicol is predominantly glucuronidated. Panobinostat does not inhibit or induce UGTs. However, in vitro studies have shown that chloramphenicol can inhibit metabolism mediated by CYPs 3A4 (strong), 2C19 (strong) and 2D6 (weak). Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Ocular use: Although chloramphenicol is systemically absorbed when used topically in the eye, the absorbed concentrations are unlikely to cause a clinically significant interaction.",See Summary
63,Panobinostat,Chlordiazepoxide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolised by CYP3A4, but does not inhibit or induce cytochromes. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on chlordiazepoxide exposure is not expected in vivo.",See Summary
64,Panobinostat,Chlorphenamine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Chlorphenamine is predominantly metabolised in the liver via CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of chlorphenamine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with chlorphenamine. Therefore, care should be taken if chlorphenamine is coadministered with panobinostat. Monitoring for chlorphenamine may be required.",See Summary
65,Panobinostat,Chlorpromazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Chlorpromazine is metabolised mainly by CYP2D6, but also by CYP1A2. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of chlorpromazine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with chlorpromazine. If coadministration is unavoidable, monitor closely for chlorpromazine toxicity. Furthermore, panobinostat and chlorpromazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
66,Panobinostat,Chlortalidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is mainly excreted unchanged in the urine and faeces. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on chlortalidone exposure is not expected in vivo.,See Summary
67,Panobinostat,Ciclosporin (Cyclosporine),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ciclosporin is a substrate of CYP3A4 and P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on ciclosporin exposure is not expected in vivo. However, ciclosporin is an inhibitor of CYP3A4 and OATP1B1. Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required.",See Summary
68,Panobinostat,Cilazapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is mainly eliminated unchanged by the kidneys. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
69,Panobinostat,Cimetidine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Cimetidine is a weak inhibitor of several CYP-enzymes (CYPs 3A4, 1A2, 2D6 and 2C19, among others). Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Cimetidine may also decrease the renal excretion of drugs due to competition for the active tubular secretion. In vitro data indicate that cimetidine also inhibits OAT1 and OCT2 but at concentrations much higher than the observed clinical concentrations. Panobinostat does not interact with this pathway. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with cimetidine is not expected.",See Summary
70,Panobinostat,Ciprofloxacin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ciprofloxacin is primarily eliminated unchanged in the kidneys by glomerular filtration and tubular secretion via OAT3. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on ciprofloxacin exposure is not expected in vivo. Ciprofloxacin is also metabolised and partially cleared through the bile and intestine. Panobinostat does not interact with this metabolic pathway. Furthermore, ciprofloxacin is a weak to moderate inhibitor of CYP3A4 and a strong inhibitor of CYP1A2. Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Panobinostat and ciprofloxacin may cause QTc interval prolongation. Coadministration is not recommended. Monitoring of ECG may be required.",See Summary
71,Panobinostat,Cisapride,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Cisapride is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on cisapride exposure is not expected in vivo. However, coadministration with other drugs that prolong the QTc interval, such as panobinostat, should be avoided.",See Summary
72,Panobinostat,Citalopram,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Citalopram is metabolised by CYPs 2C19 (38%), 2D6 (31%) and 3A4 (31%). Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of citalopram. Monitoring for citalopram toxicity may be required. Furthermore, panobinostat and citalopram may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
73,Panobinostat,Clarithromycin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Clarithromycin is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on clarithromycin exposure is not expected in vivo. Clarithromycin is also an inhibitor of CYP3A4 (strong) and P-gp and may increase concentrations of panobinostat. Coadministration of ketoconazole, a strong CYP3A4 inhibitor, and panobinostat increased panobinostat AUC and Cmax by 1.6-fold and 1.8-fold, respectively. A similar effect may occur after coadministration with clarithromycin. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, reduce the panobinostat starting dose to 10 mg. Monitor closely for panobinostat toxicity. Monitor panobinostat plasma concentrations, if available. If continuous treatment with a strong CYP3A4 inhibitor is required, a dose escalation from 10 mg to 15 mg panobinostat may be considered based on patient tolerability. In addition, panobinostat and clarithromycin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
74,Panobinostat,Clavulanic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolised (likely non-CYP mediated pathway) and excreted in the urine by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
75,Panobinostat,Clemastine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Clemastine is predominantly metabolised in the liver via CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of clemastine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with clemastine. Therefore, care should be taken when clemastine is coadministered with panobinostat. Monitoring for clemastine toxicity may be required.",See Summary
76,Panobinostat,Clindamycin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolised by CYP3A4 with in vitro data suggesting it is a CYP3A4 inhibitor. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on clindamycin exposure is not expected in vivo. Furthermore, concentrations of panobinostat may increase due to inhibition of CYP3A4. However, a clinically relevant effect on panobinostat exposure is not expected.",See Summary
77,Panobinostat,Clobetasol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of clobetasol.,See Summary
78,Panobinostat,Clofazimine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces. Panobinostat is unlikely to interfere with this elimination pathway. In vitro data suggest that clofazimine is also a CYP3A4 inhibitor and may increase concentrations of panobinostat. However, a clinically relevant effect on panobinostat exposure is not expected. Panobinostat and clofazimine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
79,Panobinostat,Clofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolysed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Panobinostat does not inhibit or induce OAT1.",See Summary
80,Panobinostat,Clomipramine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Clomipramine is metabolised by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. Clomipramine and desmethylclomipramine are both metabolised by CYP2D6. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro). A clinically relevant effect on clomipramine and desmethylclomipramine exposure is not expected due to CYP3A4 inhibition. However, panobinostat may increase concentrations of clomipramine and desmethylclomipramine due to CYP2D6 inhibition. Monitoring for clomipramine and desmethylclomipramine toxicity may be required. Furthermore, panobinostat and clomipramine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
81,Panobinostat,Clonidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in the form of the unchanged parent drug (40-60% of the dose). Panobinostat is unlikely to interfere with this elimination pathway. Clonidine is also a weak inhibitor of OCT2. Panobinostat is not transported by OCT2.",See Summary
82,Panobinostat,Clopidogrel,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clopidogrel is a prodrug and is converted to its active metabolite mainly through CYP2C19 with CYPs 3A4, 2B6 and 1A2 playing a minor role. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on clopidogrel exposure is not expected in vivo. Furthermore, clopidogrel is an inhibitor of CYP2C8 (strong), CYP2B6 (weak) and CYP2C9 (in vitro) at high concentrations. The clinical relevance of CYP2C9 inhibition is unknown. Panobinostat is not a substrate of these CYPs. However, panobinostat in combination with clopidogrel increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
83,Panobinostat,Clorazepate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolised to oxazepam by CYP3A4. Furthermore, oxazepam is mainly glucuronidated. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on clorazepate exposure is not expected in vivo. ",See Summary
84,Panobinostat,Cloxacillin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. Panobinostat is unlikely to interfere with this elimination pathway.",See Summary
85,Panobinostat,Clozapine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Clozapine is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2C19 and CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase concentrations of clozapine. However, since CYP2D6 is a minor pathway and CYP3A4 inhibition is largely in vitro, a clinically relevant effect is not expected. Furthermore, panobinostat and clozapine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG. Note: Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
86,Panobinostat,Codeine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Codeine is converted via CYP2D6 to morphine, an active metabolite with analgesic and opioid properties. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of codeine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with codeine. Therefore, care should be taken when codeine is coadministered with panobinostat. Monitoring for codeine toxicity and morphine efficacy may be required. Morphine is further metabolised by conjugation with glucuronic acid to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active). Additionally, the metabolite morphine is a substrate of P-gp. Panobinostat does not inhibit or induce UGTs or P-gp. Furthermore, codeine is converted via CYP3A4 to norcodeine, an inactive metabolite. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on codeine exposure is not expected in vivo. ",See Summary
87,Panobinostat,Colchicine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Colchicine is metabolised by CYP3A4 and is a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on colchicine exposure is not expected in vivo.,See Summary
88,Panobinostat,Cycloserine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly renally excreted via glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
89,Panobinostat,Dabigatran,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dabigatran is transported via P-gp and is renally excreted. Panobinostat does not inhibit or induce P-gp and is unlikely to interfere with the renal elimination of dabigatran. However, panobinostat in combination with dabigatran increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
90,Panobinostat,Dalteparin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dalteparin is excreted largely unchanged via the kidneys. Panobinostat is unlikely to interfere with this elimination pathway. However, panobinostat in combination with dalteparin increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
91,Panobinostat,Dapsone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is mainly by N-acetylation with a component of N-hydroxylation, and is via multiple CYP450 enzymes. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of dapsone. However, since multiple CYP enzymes are involved in the metabolism of dapsone, a clinically relevant effect on dapsone exposure is not expected.",See Summary
92,Panobinostat,Desipramine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Desipramine is metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of desipramine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with desipramine. Monitoring for desipramine toxicity may be required. Furthermore, panobinostat and desipramine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
93,Panobinostat,Desogestrel,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possibly CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on etonogestrel exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
94,Panobinostat,Dexamethasone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dexamethasone is a substrate of CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on dexamethasone exposure is not expected in vivo. However, dexamethasone has been described as a weak inducer of CYP3A4 and may decrease panobinostat plasma concentrations. The clinical relevance of this interaction is unknown as the induction of CYP3A4 by dexamethasone has not yet been established.",See Summary
95,Panobinostat,Dextropropoxyphene,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is mainly metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on dextropropoxyphene exposure is not expected in vivo.,See Summary
96,Panobinostat,Diamorphine (diacetylmorphine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolised by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Morphine is also a substrate of P-gp. Panobinostat does not inhibit or induce UGTs or P-gp.",See Summary
97,Panobinostat,Diazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolised to nordiazepam (by CYP3A4 and CYP2C19) and to temazepam (mainly by CYP3A4). Temazepam is mainly glucuronidated. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on diazepam exposure is not expected in vivo.,See Summary
98,Panobinostat,Diclofenac,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidised by CYP2C9. Panobinostat does not inhibit or induce UGTs or CYP2C9.,See Summary
99,Panobinostat,Digoxin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Digoxin is renally eliminated via the renal transporters OATP4C1 and P-gp. Panobinostat does not inhibit or induce OATP4C1 or P-gp.,See Summary
100,Panobinostat,Dihydrocodeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 5-10% of the overall metabolism. Panobinostat does not inhibit or induce UGTs. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on dihydrocodeine exposure is not expected in vivo.",See Summary
101,Panobinostat,Diltiazem,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Diltiazem is metabolised by CYP3A4 and CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase concentrations of diltiazem. Therefore, care should be taken when diltiazem is coadministered with panobinostat. Monitoring for diltiazem toxicity may be required. Furthermore, diltiazem is a moderate inhibitor of CYP3A4 and may increase concentrations of panobinostat. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required.",See Summary
102,Panobinostat,Diphenhydramine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Diphenhydramine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 1A2, 2C9 and 2C19. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of diphenhydramine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with diphenhydramine. Monitor closely for diphenhydramine toxicity if coadministration is unavoidable. Diphenhydramine is also a weak inhibitor of CYP2D6. Panobinostat is not metabolised by CYP2D6. In addition, panobinostat and diphenhydramine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
103,Panobinostat,Dipyridamole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Panobinostat does not inhibit or induce UGTs. However, panobinostat in combination with dipyridamole increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
104,Panobinostat,Disopyramide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disopyramide is metabolised by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on disopyramide exposure is not expected in vivo. However, panobinostat and disopyramide may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
105,Panobinostat,Dolasetron,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolised by CYP2D6 (10-20%) and CYP3A4 (<1%). Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) but since CYP2D6 and CYP3A4 mediated metabolism are minor pathways, a clinically relevant effect on dolasetron exposure is not expected. However, panobinostat and dolasetron may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
106,Panobinostat,Domperidone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Domperidone is mainly metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on domperidone exposure is not expected in vivo. However, panobinostat and domperidone may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
107,Panobinostat,Dopamine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. There is little potential for dopamine to affect disposition of panobinostat, or to be affected if co-administered with panobinostat.",See Summary
108,Panobinostat,Doxazosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolised mainly by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on doxazosin exposure is not expected in vivo.,See Summary
109,Panobinostat,Doxepin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Doxepin is metabolised to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. Doxepin and nordoxepin are both metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of doxepin. Therefore, care should be taken when doxepin is coadministered with panobinostat. Monitoring for doxepin toxicity may be required.",See Summary
110,Panobinostat,Doxycycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40-60% of an administered dose can be accounted for in the urine. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
111,Panobinostat,Dronabinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolised by CYP2C9 and to a lesser extent by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on dronabinol exposure is not expected in vivo.,See Summary
112,Panobinostat,Drospirenone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Drospirenone is metabolised to a minor extent via CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on drospirenone exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
113,Panobinostat,Dulaglutide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dulaglutide is degraded by endogenous endopeptidases. Panobinostat does not interact with this metabolic pathway. Furthermore, dulaglutide delays gastric emptying and could possibly decrease the absorption rate of concomitantly administered oral drugs. The clinical relevance of delayed absorption is considered to be limited.",See Summary
114,Panobinostat,Duloxetine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Duloxetine is metabolised by CYP2D6 and CYP1A2. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of duloxetine. Therefore, care should be taken when duloxetine is coadministered with panobinostat. Monitoring for duloxetine toxicity may be required.",See Summary
115,Panobinostat,Dutasteride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is mainly metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on dutasteride exposure is not expected in vivo.,See Summary
116,Panobinostat,Dydrogesterone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dydrogesterone is metabolised to dihydrodydrogesterone (possibly via CYP3A4). Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on dydrogesterone exposure is not expected in vivo.,See Summary
117,Panobinostat,Edoxaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Edoxaban is partially metabolised by CYP3A4 (<10%) and is transported via P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on edoxaban exposure is not expected in vivo. Furthermore, CYP3A4 is only a minor pathway. However, panobinostat in combination with edoxaban increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
118,Panobinostat,Eltrombopag,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (via UGT1A1 and UGT1A3) and oxidation (via CYP1A2 and CYP2C8). Panobinostat does not inhibit or induce CYP2C8, CYP1A2 or UGTs.",See Summary
119,Panobinostat,Enalapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is eliminated renally (possibly via OATs). Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on enalapril exposure is not expected in vivo.,See Summary
120,Panobinostat,Enoxaparin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is predominantly renally excreted. Panobinostat is unlikely to interfere with this metabolic pathway. However, panobinostat in combination with enoxaparin increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
121,Panobinostat,Eprosartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eprosartan is largely excreted in bile and urine as unchanged drug. Panobinostat does not interact with this elimination pathway.,See Summary
122,Panobinostat,Ertapenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor role. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
123,Panobinostat,Erythromycin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Erythromycin is a substrate of CYP3A4 and P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on erythromycin exposure is not expected in vivo. Erythromycin is also an inhibitor of CYP3A4 (moderate) and P-gp. Concentrations of panobinostat may increase due to CYP3A4 inhibition. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Furthermore, panobinostat and erythromycin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
124,Panobinostat,Escitalopram,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Escitalopram is metabolised by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro), and may increase concentrations of escitalopram. Monitoring for escitalopram toxicity may be required. Furthermore, panobinostat and escitalopram may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
125,Panobinostat,Esomeprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Esomeprazole is metabolised by CYP2C19 and CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on esomeprazole exposure is not expected in vivo. Esomeprazole is also an inhibitor of CYP2C19. Panobinostat is not metabolised by CYP2C19. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on a PBPK simulation, a clinical relevant effect on panobinostat absorption after coadministration with esomeprazole is not expected.",See Summary
126,Panobinostat,Estazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolised to its major metabolite 4-hydroxyestazolam via CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on estazolam exposure is not expected in vivo.,See Summary
127,Panobinostat,Estradiol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Estradiol is metabolised by CYP3A4, CYP1A2 and is glucuronidated. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on estradiol exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
128,Panobinostat,Ethambutol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolised by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and urine (50%). Panobinostat does not interact with this metabolic pathway.,See Summary
129,Panobinostat,Ethinylestradiol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Ethinylestradiol undergoes oxidation (CYP3A4>CYP2C9), sulfation and glucuronidation (UGT1A1). Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on ethinylestradiol exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
130,Panobinostat,Ethionamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolised in the liver; animal studies suggest involvement of flavin-containing monooxygenases. Panobinostat does not interact with this metabolic pathway.,See Summary
131,Panobinostat,Etonogestrel,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Etonogestrel is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on etonogestrel exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
132,Panobinostat,Everolimus (Immunosuppressant),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Everolimus is mainly metabolised by CYP3A4 and is a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on everolimus exposure is not expected in vivo. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
133,Panobinostat,Exenatide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exenatide is cleared mainly by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway. Exenatide delays gastric emptying and could possibly decrease the absorption rate of concomitantly administered oral drugs. The clinical relevance of delayed absorption is considered to be limited.,See Summary
134,Panobinostat,Ezetimibe,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3, and to a lesser extent by UGTs 2B15 and 2B7. Panobinostat does not inhibit or induce UGTs.",See Summary
135,Panobinostat,Famotidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is excreted via OAT1/OAT3. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on famotidine exposure is not expected in vivo. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with famotidine is not expected.",See Summary
136,Panobinostat,Felodipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on felodipine exposure is not expected in vivo.,See Summary
137,Panobinostat,Fenofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolysed to an active metabolite, fenofibric acid. In vitro data suggest that fenofibric acid inhibits OAT3. Panobinostat does not interact with this pathway.",See Summary
138,Panobinostat,Fentanyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on fentanyl exposure is not expected in vivo.,See Summary
139,Panobinostat,Fexofenadine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine is a substrate of P-gp. Panobinostat does not inhibit or induce P-gp.,See Summary
140,Panobinostat,Finasteride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on finasteride exposure is not expected in vivo.,See Summary
141,Panobinostat,Fish oils,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
142,Panobinostat,Flecainide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Flecainide is metabolised mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also renally eliminated unchanged. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of flecainide. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with flecainide. Therefore, coadministration should be approached with caution. If coadministration is necessary, monitor closely for flecainide toxicity. Furthermore, panobinostat and flecainide may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
143,Panobinostat,Flucloxacillin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Flucloxacillin is mainly renally eliminated partly by glomerular filtration and partly by active secretion via OAT1. Panobinostat does not interact with this elimination pathway. Flucloxacillin has been described as a CYP3A4 inducer and may decrease concentrations of panobinostat. However, as the mechanism and clinical relevance of this interaction is unknown, monitoring of panobinostat efficacy may be required.",See Summary
144,Panobinostat,Fluconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Fluconazole is cleared primarily by renal excretion. Panobinostat is unlikely to interfere with this elimination pathway. However, fluconazole is an inhibitor of CYPs 3A4 (moderate), 2C9 (moderate) and 2C19 (strong). Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Furthermore, panobinostat and fluconazole may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
145,Panobinostat,Flucytosine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Flucytosine is metabolised to 5-fluorouracil (5-FU). 5-FU is further metabolised by dihydropyrimidine dehydrogenase (DPD) to an inactive metabolite. Panobinostat does not interfere with this elimination pathway. However, 5-FU binds to the enzyme thymidylate synthase resulting in DNA damage. This mechanism occurs in all fast dividing cells including bone marrow cells, resulting in haematological toxicity. Panobinostat also induces haematological toxicity which could be enhanced by the use of flucytosine. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
146,Panobinostat,Fludrocortisone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolised in the liver to inactive metabolites, possibly via CYP3A. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on fludrocortisone exposure is not expected in vivo.",See Summary
147,Panobinostat,Flunitrazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolised mainly via CYP3A4 and CYP2C19. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on flunitrazepam exposure is not expected in vivo.,See Summary
148,Panobinostat,Fluoxetine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Fluoxetine is mainly metabolised by CYP2D6 and CYP2C9, and to a lesser extent by CYP2C19 and CYP3A4 to form norfluoxetine. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of fluoxetine. Therefore, care should be taken when fluoxetine is coadministered with panobinostat. Monitoring for fluoxetine toxicity may be required. Furthermore, fluoxetine is a strong inhibitor of CYP2D6 and CYP2C19. Panobinostat is not metabolised by these CYPs.",See Summary
149,Panobinostat,Fluphenazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Fluphenazine is metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of fluphenazine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with fluphenazine. If coadministration is unavoidable, monitor closely for fluphenazine toxicity. Furthermore, panobinostat and fluphenazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
150,Panobinostat,Flurazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of flurazepam. However, since multiple CYP enzymes are involved in flurazepam metabolism and flurazepam has a broad therapeutic index, a clinically relevant interaction is unlikely.",See Summary
151,Panobinostat,Fluticasone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on fluticasone exposure is not expected in vivo. Note: A clinically significant interaction is also unlikely with the topical use of fluticasone.,See Summary
152,Panobinostat,Fluvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolised by CYP2C9 (75%) and to a lesser extent by CYP3A4 (20%) and CYP2C8 (5%). Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on fluvastatin exposure is not expected in vivo. However, fluvastatin potentially inhibits CYP2C9, but the clinical relevance of CYP2C9 inhibition is unknown. Panobinostat is not metabolised by CYP2C9.",See Summary
153,Panobinostat,Fluvoxamine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Fluvoxamine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of fluvoxamine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with fluvoxamine. Therefore, care should be taken when fluvoxamine is coadministered with panobinostat. Monitoring for fluvoxamine toxicity may be required. Furthermore, fluvoxamine is also an inhibitor of CYPs 1A2 (strong), 2C19 (moderate-strong), 3A4 (moderate), 2C9 (weak-moderate) and CYP2D6 (weak). Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required.",See Summary
154,Panobinostat,Fondaparinux,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is eliminated predominantly renally. Panobinostat is unlikely to interfere with the renal elimination of fondaparinux. However, panobinostat in combination with fondaparinux increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
155,Panobinostat,Formoterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation. As multiple CYP450 and UGT enzymes catalyse the transformation the potential for a pharmacokinetic interaction is low. ",See Summary
156,Panobinostat,Fosaprepitant,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Fosaprepitant is rapidly, almost completely, converted to the active metabolite aprepitant. Panobinostat does not interact with this pathway. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on aprepitant exposure is not expected in vivo. However, during treatment aprepitant is a moderate inhibitor of CYP3A4. After treatment, aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Concentrations of panobinostat may both increase and decrease due to inhibition and induction of CYP3A4 respectively. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required during the three days of coadministration. Decreased exposure due to CYP3A4 induction after treatment with fosaprepitant is considered not to be clinically relevant.",See Summary
157,Panobinostat,Fosphenytoin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Fosphenytoin is rapidly converted to the active metabolite phenytoin. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Panobinostat does not inhibit or induce CYP2C9 or CYP2C19. However, phenytoin is a potent inducer of CYP3A4, UGT and P-gp. Concentrations of panobinostat may decrease due to strong induction of CYP3A4. The clinical relevance of this interaction is unknown as interaction studies with CYP3A inducers have not been performed. In a PBPK simulation, coadministration of rifampicin, a strong CYP3A4 inducer, and panobinostat decreased panobinostat exposure by ~ 60%. A similar effect may occur with fosphenytoin. A decrease in exposure may lead to a decreased efficacy. Therefore, coadministration should be avoided.",See Summary
158,Panobinostat,Furosemide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally (via OATs). Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on furosemide exposure is not expected in vivo. In vitro data indicate that furosemide is also an inhibitor of the renal transporters OAT1/OAT3. Panobinostat is not transported by OAT1/3.,See Summary
159,Panobinostat,Gabapentin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gabapentin is cleared mainly by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
160,Panobinostat,Gemfibrozil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is metabolised by UGT2B7. Panobinostat does not inhibit or induce UGTs. However, gemfibrozil is an inhibitor of CYP2C8 (strong), OATP1B1 and OAT3. In vitro data indicate gemfibrozil to be a strong inhibitor of CYP2C9 but in vivo data showed no clinically relevant effect on CYP2C9. Panobinostat is not a substrate of these CYPs, OATPs or OATs.",See Summary
161,Panobinostat,Gentamicin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
162,Panobinostat,Gestodene,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Gestodene is metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on gestodene exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
163,Panobinostat,Glibenclamide (Glyburide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on glibenclamide exposure is not expected in vivo.,See Summary
164,Panobinostat,Gliclazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C19. Panobinostat does not inhibit or induce CYP2C9 or CYP2C19.,See Summary
165,Panobinostat,Glimepiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is mainly metabolised by CYP2C9. Panobinostat does not inhibit or induce CYP2C9.,See Summary
166,Panobinostat,Glipizide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is mainly metabolised by CYP2C9. Panobinostat does not inhibit or induce CYP2C9.,See Summary
167,Panobinostat,Granisetron,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Granisetron is metabolised by CYP3A4 and is a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on granisetron exposure is not expected in vivo. However, panobinostat and granisetron may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
168,Panobinostat,Grapefruit juice,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Grapefruit juice is a known inhibitor of CYP3A4 and may increase concentrations of panobinostat. Therefore, coadministration should be avoided.",See Summary
169,Panobinostat,Green tea,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
170,Panobinostat,Griseofulvin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Less than 1% of a griseofulvin dose is excreted unchanged via the kidneys. Griseofulvin is also a liver microsomal enzyme inducer and may lower plasma levels, and therefore reduce the efficacy of concomitantly administered medicinal products that are metabolised by CYP3A4, such as panobinostat. The clinical relevance of this interaction is unknown. Therefore, coadministration should be approached with caution. Monitor closely for panobinostat efficacy. Monitor panobinostat plasma concentrations, if available.",See Summary
171,Panobinostat,Haloperidol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGTs 2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4 and CYP2D6). Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase concentrations of haloperidol. Therefore, care should be taken when haloperidol is coadministered with panobinostat. Monitoring for haloperidol toxicity may be required. Furthermore, panobinostat and haloperidol may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
172,Panobinostat,Heparin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Heparin is thought to be eliminated via the reticuloendothelial system. Panobinostat does not interact with this metabolic pathway. However, panobinostat in combination with heparin increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
173,Panobinostat,Hydralazine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Panobinostat does not interact with this metabolic pathway. In vitro studies have suggested that hydralazine is a mixed enzyme inhibitor, which may weakly inhibit CYP3A4 and CYP2D6. Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required.",See Summary
174,Panobinostat,Hydrochlorothiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised but is cleared by the kidneys via OAT1. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Panobinostat does not interact with this pathway.,See Summary
175,Panobinostat,Hydrocodone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on hydrocodone exposure is not expected in vivo. Furthermore, panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of hydrocodone. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with hydrocodone. Therefore, care should be taken when hydrocodone is coadministered with panobinostat. Monitoring for hydrodone toxicity may be required. ",See Summary
176,Panobinostat,Hydrocortisone (oral),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on hydrocortisone exposure is not expected in vivo.,See Summary
177,Panobinostat,Hydrocortisone (topical),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of hydrocortisone. ,See Summary
178,Panobinostat,Hydromorphone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Panobinostat does not inhibit or induce UGTs.",See Summary
179,Panobinostat,Hydroxyurea (Hydroxycarbamide),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyurea is metabolised in the liver and cleared via the lungs and kidneys. Panobinostat is unlikely to interfere with this metabolic pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
180,Panobinostat,Hydroxyzine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyzine is partly metabolised by alcohol dehydrogenase and partly by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on hydroxyine exposure is not expected in vivo. However, panobinostat and hydroxyzine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
181,Panobinostat,Ibandronic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ibandronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid.",See Summary
182,Panobinostat,Ibuprofen,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolised mainly by CYP2C9, and to a lesser extent by CYP2C8 and direct glucuronidation. Panobinostat does not inhibit or induce CYP2C9, CYP2C8 or UGTs.",See Summary
183,Panobinostat,Iloperidone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Iloperidone is metabolised by CYP3A4 and CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase concentrations of iloperidone. If coadministration is unavoidable, monitor closely for iloperidone toxicity. Furthermore, panobinostat and iloperidone may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
184,Panobinostat,Imipenem/Cilastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and to a lesser extent by active tubular secretion. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
185,Panobinostat,Imipramine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Imipramine is metabolised by CYPs 3A4, 2C19 and 1A2 to desipramine. Imipramine and desipramine are both metabolised by CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase concentrations of imipramine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with imipramine and desipramine. Monitoring for imipramine and desipramine toxicity may be required. Furthermore, panobinostat and imipramine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
186,Panobinostat,Indapamide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Indapamide is extensively metabolised by CYP450s. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) but since multiple pathways are involved in the metabolism of indapamide, a clinically relevant effect on indapamide exposure is not expected. Furthermore, OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on indapamide exposure is not expected in vivo. However, panobinostat and indapamide may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
187,Panobinostat,Insulin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
188,Panobinostat,Interferon alpha,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
189,Panobinostat,Interleukin 2 (Aldesleukin),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Interleukin-2 is mainly eliminated by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
190,Panobinostat,Ipratropium bromide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation. Panobinostat does not interact with this metabolic pathway.,See Summary
191,Panobinostat,Irbesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irbesartan is metabolised by glucuronidation and oxidation (mainly CYP2C9). Panobinostat does not inhibit or induce CYP2C9 or UGTs.,See Summary
192,Panobinostat,Iron supplements,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
193,Panobinostat,Isoniazid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
194,Panobinostat,Isosorbide dinitrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that CYP3A4 has a role in nitric oxide formation from isosorbide dinitrate. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on isosorbide dinitrate exposure is not expected in vivo.,See Summary
195,Panobinostat,Itraconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Itraconazole is primarily metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on itraconazole exposure is not expected in vivo. Itraconazole is also an inhibitor of CYP3A4 (strong), CYP2C9 (weak), P-gp and BCRP. Concentrations of panobinostat may increase due to strong inhibition of CYP3A4. Coadministration of ketoconazole, a strong CYP3A4 inhibitor, and panobinostat increased panobinostat AUC and Cmax by 1.6-fold and 1.8-fold, respectively. A similar effect may occur after coadministration with itraconazole. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, reduce the panobinostat starting dose to 10 mg. Monitor closely for panobinostat toxicity. Monitor panobinostat plasma concentrations, if available. If continuous treatment with a strong CYP3A4 inhibitor is required, a dose escalation from 10 mg to 15 mg panobinostat may be considered based on patient tolerability.",See Summary
196,Panobinostat,Ivabradine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Ivabradine is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on ivabradine exposure is not expected in vivo. However, panobinostat and ivabradine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
197,Panobinostat,Kanamycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kanamycin is eliminated unchanged predominantly via glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
198,Panobinostat,Ketoconazole,"
Potential Interaction
","
Very Low
","Coadministration has been studied but should be approached with caution. Ketoconazole is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on ketoconazole exposure is not expected in vivo. However, ketoconazole is an inhibitor of CYP3A4 (strong) and P-gp and may increase concentrations of panobinostat. Coadministration of ketoconazole, a strong CYP3A4 inhibitor, and panobinostat increased panobinostat AUC and Cmax by 1.6-fold and 1.8-fold, respectively. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, reduce the panobinostat starting dose to 10 mg. Monitor closely for panobinostat toxicity. Monitor panobinostat plasma concentrations, if available. If continuous treatment with a strong CYP3A4 inhibitor is required, a dose escalation from 10 mg to 15 mg panobinostat may be considered based on patient tolerability.",See Summary
199,Panobinostat,Labetalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated (via UGT1A1 and UGT2B7). Panobinostat does not inhibit or induce UGTs.,See Summary
200,Panobinostat,Lacidipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on lacidipine exposure is not expected in vivo.,See Summary
201,Panobinostat,Lactulose,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only. Panobinostat does not interact with this metabolic pathway.,See Summary
202,Panobinostat,Lansoprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on lansoprazole exposure is not expected in vivo. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with lansoprazole is not expected.",See Summary
203,Panobinostat,Lercanidipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on lercanidipine exposure is not expected in vivo.,See Summary
204,Panobinostat,Levocetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
205,Panobinostat,Levofloxacin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Levofloxacin is renally eliminated mainly by glomerular filtration and active secretion (possibly OCT2). Panobinostat is an inhibitor of OCT2 in vitro but a clinically relevant effect on levofloxacin exposure is not expected. Furthermore, panobinostat and levofloxacin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
206,Panobinostat,Levomepromazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Levomepromazine is metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of levomepromazine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with levomepromazine. If coadministration is unavoidable, monitor closely for levomepromazine toxicity. Furthermore, panobinostat and levomepromazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
207,Panobinostat,Levonorgestrel,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Levonorgestrel is mainly metabolised by CYP3A4 and is glucuronidated to a minor extent. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on levonorgestrel exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
208,Panobinostat,Levonorgestrel (Emergency Contraception),"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Levonorgestrel is mainly metabolised by CYP3A4 and is glucuronidated to a minor extent. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on levonorgestrel exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
209,Panobinostat,Levothyroxine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levothyroxine is metabolised by deiodination (by enzymes of deiodinase family) and glucuronidation. Panobinostat does not interact with this metabolic pathway.,See Summary
210,Panobinostat,Lidocaine (Lignocaine),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on lidocaine exposure is not expected in vivo.,See Summary
211,Panobinostat,Linagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Linagliptin is mainly eliminated as parent compound in faeces with metabolism by CYP3A4 representing a minor metabolic pathway. Linagliptin is also a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on linagliptin exposure is not expected in vivo. However, linagliptin is a weak inhibitor of CYP3A4 and may increase concentrations of panobinostat. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be necessary.",See Summary
212,Panobinostat,Linezolid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linezolid undergoes non-CYP mediated metabolism. Panobinostat does not interact with this metabolic pathway.,See Summary
213,Panobinostat,Liraglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Liraglutide is degraded by endogenous endopeptidases. Panobinostat does not interact with this metabolic pathway.,See Summary
214,Panobinostat,Lisinopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
215,Panobinostat,Lithium,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate therefore no pharmacokinetic interaction is expected. However, panobinostat and lithium may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
216,Panobinostat,Live vaccines,"
Do Not Coadminister
","
Very Low
","Coadministration of live vaccines (such as BCG vaccine; measles, mumps and rubella vaccines; varicella vaccines; typhoid vaccines; rotavirus vaccines; yellow fever vaccines; oral polio vaccine) has not been studied. In patients, who are receiving cytotoxics or other immunosuppressant drugs, use of live vaccines for immunisation is contraindicated. If coadministration is judged clinically necessary, use with extreme caution since generalised infections can occur.",See Summary
217,Panobinostat,Loperamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is mainly metabolised by CYP3A4 and CYP2C8, and is a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on loperamide exposure is not expected in vivo. ",See Summary
218,Panobinostat,Loratadine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase concentrations of loratadine. However, since CYP3A4 inhibition is largely in vitro and CYP2D6 metabolism is a minor pathway, a clinically relevant interaction is not expected. ",See Summary
219,Panobinostat,Lorazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam undergoes non-CYP-mediated elimination. Panobinostat does not interact with this metabolic pathway.,See Summary
220,Panobinostat,Lormetazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated. Panobinostat does not inhibit or induce UGTs.,See Summary
221,Panobinostat,Losartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. Panobinostat does not inhibit or induce CYP2C9.,See Summary
222,Panobinostat,Lovastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lovastatin is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on lovastatin exposure is not expected in vivo.,See Summary
223,Panobinostat,Macitentan,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on macitentan exposure is not expected in vivo.",See Summary
224,Panobinostat,Magnesium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in the kidney, mainly by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.",See Summary
225,Panobinostat,Maprotiline,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Maprotiline is mainly metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of maprotiline. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with maprotiline. Therefore, care should be taken. Monitoring for maprotiline toxicity may be required.",See Summary
226,Panobinostat,Medroxyprogesterone (depot),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on medroxyprogesterone exposure is not expected in vivo.,See Summary
227,Panobinostat,Medroxyprogesterone (non-depot),"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Medroxyprogesterone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on medroxyprogesterone exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
228,Panobinostat,Mefenamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolised by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9. Panobinostat does not inhibit or induce CYP2C9 or UGTs.,See Summary
229,Panobinostat,Megestrol acetate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Megestrol acetate is mainly eliminated in the urine. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
230,Panobinostat,Meropenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney with in vitro data suggesting it is a substrate of OAT3>OAT1. Panobinostat is an inhibitor of OAT3 in vitro but a clinically significant effect on meropenem exposure is not expected.,See Summary
231,Panobinostat,Mesalazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolised to N-acetyl-mesalazine by N-acetyltransferase. Panobinostat does not interact with this metabolic pathway.,See Summary
232,Panobinostat,Metamizole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Metamizole is metabolised by hydrolysis to the active metabolite MAA in the gastrointestinal tract. Metamizole is metabolised in serum and excreted via urine (90%) and faeces (10%). Panobinostat does not interact with this metabolic pathway. However, metamizole is an inducer of CYP3A4 and may decrease panobinostat concentrations. The clinical relevance of this interaction is unknown. Therefore, coadministration should be approached with caution. Monitor closely for panobinostat efficacy. Monitor panobinostat plasma concentrations, if available.",See Summary
233,Panobinostat,Metformin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine and is a substrate of OCT1/2/3, MATE1 and MATE2K. Panobinostat is an inhibitor of OCT1/2 in vitro but a clinically relevant effect on metformin exposure is not expected in vivo.",See Summary
234,Panobinostat,Methadone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Methadone is demethylated by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on methadone exposure is not expected in vivo. However, panobinostat and methadone may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
235,Panobinostat,Methyldopa,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. Panobinostat is unlikely to interfere with this elimination pathway.",See Summary
236,Panobinostat,Methylphenidate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylphenidate is not metabolised by CYP450s to a clinically relevant extent and does not inhibit or induce CYP450s. ,See Summary
237,Panobinostat,Methylprednisolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on methylprednisolone exposure is not expected in vivo.,See Summary
238,Panobinostat,Metoclopramide,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Metoclopramide is partially metabolised by the CYP450 system (mainly CYP2D6). Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of metoclopramide. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with metoclopramide. Therefore, care should be taken when metoclopramide is coadministered with panobinostat. Monitoring for metoclopramide toxicity may be required.",See Summary
239,Panobinostat,Metolazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is largely excreted unchanged in the urine. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on metolazone exposure is not expected in vivo.,See Summary
240,Panobinostat,Metoprolol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Metoprolol is mainly metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of metoprolol. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with metoprolol. Therefore, care should be taken when metoprolol is coadministered with panobinostat. Monitoring for blood pressure may be required.",See Summary
241,Panobinostat,Metronidazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Metronidazole is eliminated via glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway. Furthermore, elevated plasma concentrations have been reported for some CYP3A substrates (e.g. tacrolimus, ciclosporin) with metronidazole. However, metronidazole did not increase concentrations of several CYP3A probe drugs (e.g. midazolam, alprazolam). Since the mechanism of the interaction with CYP3A has not yet been identified, an interaction with panobinostat cannot be excluded. Monitoring for panobinostat toxicity may be required.",See Summary
242,Panobinostat,Mexiletine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied should be approached with caution. Mexiletine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of mexiletine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with mexiletine. Therefore, coadministration should be approached with caution. If coadministration is necessary, monitor closely for mexiletine toxicity. Consider monitoring of mexiletine plasma concentrations, if available.",See Summary
243,Panobinostat,Mianserin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Mianserin is metabolised by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of mianserin. Therefore, care should be taken when mianserin is coadministered with panobinostat. Monitoring for mianserin toxicity may be required.",See Summary
244,Panobinostat,Miconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Miconazole is extensively metabolised by the liver. Panobinostat is unlikely to interact with this unspecified metabolic pathway. However, miconazole is an inhibitor of CYP2C9 (moderate) and CYP3A4 (strong). Concentrations of panobinostat may increase due to strong inhibition of CYP3A4. Coadministration of ketoconazole, a strong CYP3A4 inhibitor, and panobinostat increased panobinostat AUC and Cmax by 1.6-fold and 1.8-fold, respectively. A similar effect may occur after coadministration with miconazole. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, reduce the panobinostat starting dose to 10 mg. Monitor closely for panobinostat toxicity. Monitor panobinostat plasma concentrations, if available. If continuous treatment with a strong CYP3A4 inhibitor is required, a dose escalation from 10 mg to 15 mg panobinostat may be considered based on patient tolerability. Note: after dermal application miconazole is only minimally absorbed. Therefore, no clinical relevant interaction is expected.",See Summary
245,Panobinostat,Midazolam (oral),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on midazolam exposure is not expected in vivo. Furthermore, in a PBPK simulation, coadministration of panobinostat and midazolam increased midazolam exposure by ~4%.",See Summary
246,Panobinostat,Midazolam (parenteral),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on midazolam exposure is not expected in vivo. Furthermore, in a PBPK simulation, coadministration of panobinostat and midazolam increased midazolam exposure by ~4%.",See Summary
247,Panobinostat,Milnacipran,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%). Panobinostat is unlikely to interact with this elimination pathway.",See Summary
248,Panobinostat,Mirtazapine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro), and may increase concentrations of mirtazapine. Therefore, care should be taken when mirtazapine is coadministered with panobinostat. Monitoring for mirtazapine toxicity may be required. ",See Summary
249,Panobinostat,Mometasone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on mometasone exposure is not expected in vivo. Note: A clinically relevant interaction is not expected with the topical use of mometasone.,See Summary
250,Panobinostat,Montelukast,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolised by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on montelukast exposure is not expected in vivo.,See Summary
251,Panobinostat,Morphine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Morphine is also a substrate of P-gp. Panobinostat does not inhibit or induce UGTs or P-gp.",See Summary
252,Panobinostat,Moxifloxacin,"
Potential Interaction
","
Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. Panobinostat does not inhibit or induce UGTs. However, the product labels for moxifloxacin contraindicate its use in the presence of other drugs that prolong the QT interval, such as panobinostat. If coadministration is unavoidable, use with extreme caution and monitor ECG.",See Summary
253,Panobinostat,Mycophenolate,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7. Panobinostat does not inhibit or induce UGTs. The active metabolite of mycophenolate, mycophenolic acid, is an inhibitor of OAT1/OAT3. Panobinostat is not transported by OATs. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
254,Panobinostat,Nadroparin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Nadroparin is excreted renally by a nonsaturable mechanism. Panobinostat is unlikely to interfere with this elimination pathway. However, panobinostat in combination with nadroparin increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
255,Panobinostat,Nandrolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nandrolone is metabolised in the liver by alpha-reductase. Panobinostat does not interact with this metabolic pathway.,See Summary
256,Panobinostat,Naproxen,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A2. Panobinostat does not inhibit or induce UGTs, CYP2C9 or CYP1A2.",See Summary
257,Panobinostat,Nateglinide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolised by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on nateglinide exposure is not expected in vivo.,See Summary
258,Panobinostat,Nebivolol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Nebivolol metabolism involves CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of nebivolol. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with nebivolol. Therefore, care should be taken when nebivolol is coadministered with panobinostat. Monitoring for blood pressure may be required",See Summary
259,Panobinostat,Nefazodone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Nefazodone is metabolised mainly by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on nefazodone exposure is not expected in vivo. However, nefazodone is a strong inhibitor of CYP3A4 and may increase concentrations of panobinostat. Coadministration of ketoconazole, a strong CYP3A4 inhibitor, and panobinostat increased panobinostat AUC and Cmax by 1.6-fold and 1.8-fold, respectively. A similar effect may occur after coadministration with nefazodone. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, reduce the panobinostat starting dose to 10 mg. Monitor closely for panobinostat toxicity. Monitor panobinostat plasma concentrations, if available. If continuous treatment with a strong CYP3A4 inhibitor is required, a dose escalation from 10 mg to 15 mg panobinostat may be considered based on patient tolerability.",See Summary
260,Panobinostat,Nicardipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) but a clinically relevant effect on nicardipine exposure is not expected. However, nicardipine is a weak inhibitor of CYP3A4 and may increase concentrations of panobinostat. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required.",See Summary
261,Panobinostat,Nicotinamide (Niacinamide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolised by xanthine oxidase and aldehyde oxidase. Panobinostat does not interact with this metabolic pathway.,See Summary
262,Panobinostat,Nifedipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on nifedipine exposure is not expected in vivo.,See Summary
263,Panobinostat,Nimesulide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolised in the liver following multiple pathways including CYP2C9. Panobinostat does not inhibit or induce CYP2C9.,See Summary
264,Panobinostat,Nisoldipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on nisoldipine exposure is not expected in vivo.,See Summary
265,Panobinostat,Nitrendipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolised mainly by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on nitrendipine exposure is not expected in vivo.,See Summary
266,Panobinostat,Nitrofurantoin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolised in the liver via glucuronidation and N-acetylation, and partly eliminated in the urine as unchanged drug (30-40%). Panobinostat does not inhibit or induce UGTs and is unlikely to interfere with the renal elimination of nitrofurantoin.",See Summary
267,Panobinostat,Norelgestromin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Norelgestromin is metabolised to norgestrel (possibly by CYP3A4). Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on norelgestromin exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
268,Panobinostat,Norethisterone (Norethindrone),"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Norethisterone is extensively biotransformed, first by reduction and then by sulfate and glucuronide conjugation. Panobinostat does not interact with this metabolic pathway. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
269,Panobinostat,Norgestimate,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Norgestimate is rapidly deacetylated to the active metabolite which is further metabolised via CYP450. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase concentrations of norgestimate. The clinical relevance of this interaction is unknown. Furthermore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
270,Panobinostat,Norgestrel,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is mainly metabolised by CYP3A4 and is glucuronidated to a minor extent. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on levonorgestrel exposure is not expected in vivo. However, the effect of oral contraceptives can be reduced by the registered comedication dexamethasone. Therefore, women using hormonal contraceptives should add a barrier method as a second form of contraception while taking panobinostat in combination with dexamethasone and bortezomib.",See Summary
271,Panobinostat,Nortriptyline,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Nortriptyline is metabolised mainly by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of nortriptyline. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with nortriptyline. Monitoring for nortriptyline toxicity may be required. Furthermore, panobinostat and nortriptyline may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
272,Panobinostat,Nystatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected.",See Summary
273,Panobinostat,Ofloxacin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ofloxacin is renally eliminated unchanged by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Panobinostat is unlikely to interfere with this elimination pathway. However, panobinostat and ofloxacin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
274,Panobinostat,Olanzapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolised mainly by CYP1A2 (major) and CYP2D6, but also by glucuronidation (UGT1A4). Panobinostat is a weak inhibitor of CYP2D6. However, since CYP2D6 is a minor pathway, a clinically relevant effect on olanzapine exposure is not expected.",See Summary
275,Panobinostat,Olmesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan which is eliminated in the faeces and urine. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
276,Panobinostat,Omeprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Omeprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on omeprazole exposure is not expected in vivo. Omeprazole is also an inducer of CYP1A2 and an inhibitor of CYP2C19. Panobinostat is not metabolised by CYP1A2 or CYP2C19. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with omeprazole is not expected.",See Summary
277,Panobinostat,Ondansetron,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Ondansetron is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2D6. Ondansetron is also a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) but a clinically relevant effect on ondansetron exposure is not expected. However, panobinostat and ondansetron may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
278,Panobinostat,Oxazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated. Panobinostat does not inhibit or induce UGTs.,See Summary
279,Panobinostat,Oxcarbazepine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Oxcarbazepine is extensively metabolised to the active metabolite monohydroxyderivate (MHD) through cystolic enzymes. Panobinostat does not interact with this metabolic pathway. Both oxcarbazepine and MHD are inducers of CYP3A4 (moderate) and CYP3A5, and are inhibitors of CYP2C19. Concentrations of panobinostat may decrease due to induction of CYP3A4. The clinical relevance of this interaction is unknown as interaction studies with CYP3A inducers have not been performed. Decreased exposure may lead to decreased efficacy. Therefore, coadministration should be approached with caution. Monitor closely for panobinostat efficacy. Monitor panobinostat plasma concentrations, if available.",See Summary
280,Panobinostat,Oxprenolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised via glucuronidation. Panobinostat does not inhibit or induce UGTs.,See Summary
281,Panobinostat,Oxycodone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Oxycodone is metabolised principally to noroxycodone via CYP3A and oxymorphone via CYP2D6. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on noroxycodone exposure is not expected in vivo. However, panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of oxycodone. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with oxycodone. Oxymorphone is 14 times more potent than oxycodone but oxymorphone concentrations may decrease due to CYP2D6 inhibition. Therefore, care should be taken when oxycodone is coadministered with panobinostat. Monitoring for oxycodone toxicity and efficacy may be required.",See Summary
282,Panobinostat,Paliperidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4. Panobinostat is a weak inhibitor of CYP2D6 and an inhibitor of OCT1, OCT2 and CYP3A4 in vitro. However, a clinically relevant effect on paliperidone exposure is not expected.",See Summary
283,Panobinostat,Palonosetron,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Palonosetron is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2. Palonosetron is also a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) but a clinically relevant effect on palonosetron exposure is not expected.,See Summary
284,Panobinostat,Pamidronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pamidronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
285,Panobinostat,Pantoprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYPs 3A4, 2D6 and 2C9. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) but since CYP3A4 and CYP2D6 mediated metabolism are minor pathways, a clinically relevant effect on pantoprazole exposure is not expected. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with pantoprazole is not expected.",See Summary
286,Panobinostat,Para-aminosalicylic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
287,Panobinostat,Paracetamol (Acetaminophen),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolised by glucuronidation (via UGTs 1A9 (major), 1A6, 1A1, and 2B15) sulfation, and to a lesser extent, by oxidation (CYPs 2E1 (major), 1A2, 3A4 and 2D6). Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro). However, since CYP2D6 and CYP3A4 are minor pathways, a clinically significant effect on paracetamol exposure is not expected.",See Summary
288,Panobinostat,Paroxetine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Paroxetine is mainly metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of paroxetine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with paroxetine. Therefore, care should be taken. Monitoring for paroxetine toxicity may be required. Paroxetine is also an inhibitor of CYP2D6 (strong) and CYP2C9. Panobinostat is not metabolised by these CYPs.",See Summary
289,Panobinostat,Peginterferon alfa-2a,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored of coadministered.",See Summary
290,Panobinostat,Penicillins,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on penicillins exposure is not expected in vivo.,See Summary
291,Panobinostat,Perazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is mainly metabolised by CYPs 1A2, 3A4 and 2C19, and to a lesser extent by CYPs 2C9, 2D6 and 2E1, with oxidation via FMO3. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak). However, since CYP2D6 is a minor pathway and CYP3A4 inhibition is largely in vitro, a clinically relevant effect is not expected.",See Summary
292,Panobinostat,Periciazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of periciazine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with periciazine. Therefore, coadministration should be approached with caution. If coadministration is necessary, monitor closely for periciazine toxicity.",See Summary
293,Panobinostat,Perindopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolised to other inactive metabolites. Elimination occurs predominantly via the urine. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
294,Panobinostat,Perphenazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Perphenazine is metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of perphenazine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with perphenazine. If coadministration is necessary, monitor closely for perphenazine toxicity. Furthermore, panobinostat and perphenazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
295,Panobinostat,Pethidine (Meperidine),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolised mainly by CYP2B6 and to a lesser extent by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on pethidine exposure is not expected in vivo.,See Summary
296,Panobinostat,Phenelzine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolised by oxidation via monoamine oxidase and to a lesser extent by acetylation. Panobinostat does not interact with this metabolic pathway.,See Summary
297,Panobinostat,Phenobarbital (Phenobarbitone),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Phenobarbital is metabolised by CYP2C19 and CYP2C9 (major pathway), and to a lesser extent by CYP2E1. Panobinostat does not inhibit or induce CYPs 2C19, 2C9 or 2E1. However, phenobarbital is a strong inducer of CYPs 3A4, 2C9, 2C8 and UGTs. Concentrations of panobinostat may decrease due to strong induction of CYP3A4. The clinical relevance of this interaction is unknown as interaction studies with CYP3A inducers have not been performed. In a PBPK simulation, coadministration of rifampicin, a strong CYP3A4 inducer, and panobinostat decreased panobinostat exposure by ~ 60%. A similar effect may occur with phenobarbital. A decrease in exposure may lead to a decreased efficacy. Therefore, coadministration should be avoided.",See Summary
298,Panobinostat,Phenprocoumon,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Phenprocoumon is mainly metabolised by CYP2C9 and CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on phenprocoumon exposure is not expected in vivo. However, panobinostat in combination with phenprocoumon increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
299,Panobinostat,Phenytoin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Panobinostat does not inhibit or induce CYP2C9 or CYP2C19. However, phenytoin is a strong inducer of CYP3A4, UGT and P-gp. Concentrations of panobinostat may decrease due to strong induction of CYP3A4. The clinical relevance of this interaction is unknown as interaction studies with CYP3A inducers have not been performed. In a PBPK simulation, coadministration of rifampicin, a strong CYP3A4 inducer, and panobinostat decreased panobinostat exposure by ~ 60%. A similar effect may occur with phenytoin and a decrease in exposure may lead to a decreased efficacy. Therefore, coadministration should be avoided.",See Summary
300,Panobinostat,Phytomenadione (Vitamin K),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. An in vitro study found that the only CYP450 enzyme involved in phytomenadione metabolism was CYP4F2. Panobinostat does not inhibit or induce CYP4F2.,See Summary
301,Panobinostat,Pimozide,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but is contraindicated. Pimozide is mainly metabolised by CYP3A4 and CYP2D6, and to a lesser extent by CYP1A2. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) and may increase pimozide exposure. Furthermore, the product labels for pimozide contraindicate its use in the presence of other drugs that prolong the QT interval, such as panobinostat.",See Summary
302,Panobinostat,Pindolol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Pindolol is partly metabolised to hydroxymetabolites (possibly via CYP2D6) and partly eliminated unchanged in the urine. Panobinostat is a weak inhibitor of CYP2D6 and may increase pindolol exposure. Therefore, care should be taken when pindolol is coadministered with panobinostat. Monitoring for blood pressure may be required.",See Summary
303,Panobinostat,Pioglitazone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on pioglitazone exposure is not expected in vivo.",See Summary
304,Panobinostat,Pipotiazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of pipotiazine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with pipotiazine. If coadministration is necessary, monitor closely for pipotiazine toxicity. Furthermore, panobinostat and pipotiazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
305,Panobinostat,Piroxicam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolised by CYP2C9. Panobinostat does not inhibit or induce CYP2C9.,See Summary
306,Panobinostat,Pitavastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Pitavastatin is also a substrate of OATP1B1. Panobinostat is an inhibitor of OATP1B1 in vitro but a clinically relevant effect on pitavastatin exposure is not expected in vivo.,See Summary
307,Panobinostat,Posaconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Posaconazole is primarily metabolised by UGTs and is a substrate of P-gp. Panobinostat does not inhibit or induce UGTs or P-gp. However, posaconazole is a strong inhibitor of CYP3A and may increase concentrations of panobinostat. Coadministration of ketoconazole, a strong CYP3A4 inhibitor, and panobinostat increased panobinostat AUC and Cmax by 1.6-fold and 1.8-fold, respectively. A similar effect may occur after coadministration with posaconazole. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, reduce the panobinostat starting dose to 10 mg. Monitor closely for panobinostat toxicity. Monitor panobinostat plasma concentrations, if available. If continuous treatment with a strong CYP3A4 inhibitor is required, a dose escalation from 10 mg to 15 mg panobinostat may be considered based on patient tolerability.",See Summary
308,Panobinostat,Potassium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on limited data available an interaction appears unlikely. Potassium is renally eliminated. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
309,Panobinostat,Prasugrel,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6, and to a lesser extent by CYP2C9 and CYP2C19. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on prasugrel exposure is not expected in vivo. However, panobinostat in combination with prasugrel increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
310,Panobinostat,Pravastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pravastatin is minimally metabolised via CYP enzymes and is a substrate of OATP1B1. Panobinostat is an inhibitor of CYP3A4 and OATP1B1 in vitro but a clinically relevant effect on pravastatin exposure is not expected in vivo.,See Summary
311,Panobinostat,Prazosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin is extensively metabolised, primarily by demethylation and conjugation. Panobinostat does not interact with this metabolic pathway.",See Summary
312,Panobinostat,Prednisolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone undergoes hepatic metabolism via CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on prednisolone exposure is not expected in vivo.,See Summary
313,Panobinostat,Prednisone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on prednisone exposure is not expected in vivo.,See Summary
314,Panobinostat,Pregabalin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Pregabalin is cleared mainly by glomerular filtration (90% as unchanged drug). Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
315,Panobinostat,Prochlorperazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of prochlorperazine. Therefore, if coadministration is unavoidable, monitor closely for prochlorperazine toxicity. Furthermore, panobinostat and prochlorperazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
316,Panobinostat,Promethazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Promethazine is metabolised by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of promethazine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with promethazine. If coadministration is necessary, monitor closely for promethazine toxicity. Furthermore, panobinostat and promethazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
317,Panobinostat,Propafenone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Propafenone is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on propafenone exposure is not expected in vivo. Panobinostat is also a weak inhibitor of CYP2D6 and may increase concentrations of propafenone. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with propafenone. Therefore, coadministration should be approached with caution. If coadministration is necessary, monitor closely for propafenone toxicity.",See Summary
318,Panobinostat,Propranolol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Propranolol is metabolised by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Panobinostat is a weak inhibitor of CYP2D6 and may increase propranolol exposure. Therefore, care should be taken when propranolol is coadministered with panobinostat. Monitoring for blood pressure may be required.",See Summary
319,Panobinostat,Prucalopride,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly renally eliminated, partly by active secretion by renal transporters. Prucalopride is also a substrate of P-gp. Panobinostat is unlikely to interfere with this elimination pathway.",See Summary
320,Panobinostat,Pyrazinamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolised by xanthine oxidase. Panobinostat does not interact with this metabolic pathway.,See Summary
321,Panobinostat,Pyridoxine (Vitamin B6),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
322,Panobinostat,Quetiapine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is primarily metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on quetiapine exposure is not expected.,See Summary
323,Panobinostat,Quinapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on quinapril exposure is not expected in vivo.,See Summary
324,Panobinostat,Quinidine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Quinidine is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2E1. Quinidine is also a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on quinidine exposure is not expected in vivo. However, quinidine is an inhibitor of CYP2D6 (strong), CYP3A4 (weak) and P-gp (moderate). Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Furthermore, panobinostat and quinidine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
325,Panobinostat,Rabeprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolised via non-enzymatic reduction and to a lesser extent by CYP2C19 and CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on rabeprazole exposure is not expected in vivo. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with rabeprazole is not expected.",See Summary
326,Panobinostat,Ramipril,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolised to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Panobinostat does not interact with this metabolic pathway.",See Summary
327,Panobinostat,Ranitidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranitidine is excreted via OAT1/OAT3. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on ranitidine exposure is not expected in vivo. Furthermore, the aqueous solubility of panobinostat is pH dependent, with higher pH resulting in lower solubility. Coadministration of panobinostat with drugs that elevate the gastric pH has not been evaluated in vitro or in a clinical trial. However, based on PBPK simulations, a clinical relevant effect on panobinostat absorption after coadministration with aluminium hydroxide is not expected.",See Summary
328,Panobinostat,Ranolazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Ranolazine is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6. Ranolazine is also a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak), but a clinically relevant effect on ranolazine exposure is not expected. However, ranolazine is a weak inhibitor of P-gp, CYP3A4 and CYP2D6. Concentrations of panobinostat may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Furthermore, panobinostat and ranolazine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
329,Panobinostat,Reboxetine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on reboxetine exposure is not expected in vivo. Furthermore, in vitro data indicate reboxetine to be a weak inhibitor of CYP3A4 but in vivo data showed no inhibitory effect on CYP3A4. Therefore, no effect on panobinostat exposure is expected.",See Summary
330,Panobinostat,Repaglinide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolised by CYP2C8 and CYP3A4, with clinical data indicating it is a substrate of OATP1B1. Panobinostat is an inhibitor of CYP3A4 and OATP1B1 in vitro but a clinically relevant effect on repaglinide exposure is not expected in vivo.",See Summary
331,Panobinostat,Retinol (Vitamin A),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver but retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Panobinostat does not interact with this metabolic pathway.",See Summary
332,Panobinostat,Riboflavin (Vitamin B2),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
333,Panobinostat,Rifabutin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Rifabutin is metabolised by CYP3A and via deacetylation. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on rifabutin exposure is not expected in vivo. Rifabutin is also a strong CYP3A4 and P-gp inducer. Concentrations of panobinostat may decrease due to strong induction of CYP3A4. No clinical interaction studies with CYP3A inducers have been performed and so the clinical relevance of this interaction is unknown. In a PBPK simulation, coadministration of rifampicin, a strong CYP3A4 inducer, and panobinostat decreased panobinostat exposure by ~ 60%. A similar effect may occur with rifabutin and a decrease in exposure may lead to a decreased efficacy. Therefore, coadministration should be avoided.",See Summary
334,Panobinostat,Rifampicin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Rifampicin is metabolised via deacetylation. Panobinostat does not interact with this metabolic pathway. Rifampicin is also a strong CYP3A4 and P-gp inducer. Concentrations of panobinostat may decrease due to strong induction of CYP3A4. No clinical interaction studies with CYP3A inducers have been performed and so the clinical relevance of this interaction is unknown. In a PBPK simulation, coadministration of rifampicin and panobinostat decreased panobinostat exposure by ~ 60%. A decrease in exposure may lead to a decreased efficacy. Therefore, coadministration should be avoided.",See Summary
335,Panobinostat,Rifapentine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Rifapentine is metabolised via deacetylation. Panobinostat does not interact with this metabolic pathway. Rifapentine is also a strong CYP3A4, CYP2C8 and P-gp inducer. Concentrations of panobinostat may decrease due to strong induction of CYP3A4. No clinical interaction studies with CYP3A inducers have been performed and so the clinical relevance of this interaction is unknown. In a PBPK simulation, coadministration of rifampicin, a strong CYP3A4 inducer, and panobinostat decreased panobinostat exposure by ~ 60%. A similar effect may occur with rifapentine and a decrease in exposure may lead to a decreased efficacy. Therefore, coadministration should be avoided.",See Summary
336,Panobinostat,Rifaximin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug. Panobinostat is unlikely to interfere with this elimination pathway.",See Summary
337,Panobinostat,Risperidone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Risperidone is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Risperidone is also a substrate of P-gp. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of risperidone. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with risperidone. Therefore, care should be taken. Monitoring for risperidone toxicity may be required.",See Summary
338,Panobinostat,Rivaroxaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Rivaroxaban is partly metabolised in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine. Rivaroxaban is also a substrate of P-gp and BCRP. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on rivaroxaban exposure is not expected in vivo. However, panobinostat in combination with rivaroxaban increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
339,Panobinostat,Rosiglitazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP2C9. Panobinostat does not inhibit or induce CYP2C8 or CYP2C9.,See Summary
340,Panobinostat,Rosuvastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosuvastatin is largely excreted unchanged via the faeces via OATP1B1 and is a substrate of BCRP. Panobinostat is an inhibitor of OATP1B1 in vitro but a clinically relevant effect on rosuvastatin exposure is not expected in vivo.,See Summary
341,Panobinostat,Salbutamol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolised to the inactive salbutamol-4-O-sulphate. Panobinostat does not interact with this metabolic pathway.,See Summary
342,Panobinostat,Salmeterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on salmeterol exposure is not expected in vivo. Furthermore, the systemic exposure of salmeterol is low.",See Summary
343,Panobinostat,Saxagliptin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolised by CYP3A4 and is a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on saxagliptin exposure is not expected in vivo. ,See Summary
344,Panobinostat,Senna,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces but also in other secretions. No clinically significant interactions are known.,See Summary
345,Panobinostat,Sertindole,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but is contraindicated. Sertindole is metabolised by CYP2D6 and CYP3A4. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of sertindole. Furthermore, the product labels for sertindole contraindicate its use in the presence of other drugs that prolong the QT interval, such as panobinostat.",See Summary
346,Panobinostat,Sertraline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolised by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro). However, since CYP2D6 and CYP3A4 are minor pathways, no clinically relevant effect on sertraline exposure is expected.",See Summary
347,Panobinostat,Sildenafil (Pulmonary Arterial Hypertension),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C9. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on sildenafil exposure is not expected in vivo.,See Summary
348,Panobinostat,Simvastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolised by CYP3A4. Simvastatin is also a substrate of BCRP and the active metabolite is a substrate of OATP1B1. Panobinostat is an inhibitor of CYP3A4 and OATP1B1 in vitro but a clinically relevant effect on simvastatin exposure is not expected in vivo.,See Summary
349,Panobinostat,Sirolimus,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sirolimus is metabolised by CYP3A4 and is a substrate of P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on sirolimus exposure is not expected in vivo. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
350,Panobinostat,Sitagliptin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, and P-gp) and metabolism by CYP3A4 represents a minor metabolic pathway. Panobinostat is an inhibitor of OAT3 and CYP3A4 in vitro but a clinically relevant effect on sitagliptin exposure is not expected in vivo.",See Summary
351,Panobinostat,Sodium nitroprusside,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. Panobinostat does not interact with this metabolic pathway.",See Summary
352,Panobinostat,Sotalol,"
Potential Interaction
","
Low
","Coadministration has not been studied but should be used with extreme caution. Sotalol is excreted unchanged via renal elimination. Panobinostat is unlikely to interfere with this elimination pathway. However, the product labels for sotalol advise extreme caution if given with other drugs that prolong the QT interval, such as panobinostat.",See Summary
353,Panobinostat,Spectinomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spectinomycin is predominantly eliminated unchanged in the kidneys via glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
354,Panobinostat,Spironolactone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolised by the flavin containing monooxygenases. Panobinostat does not interact with this metabolic pathway.,See Summary
355,Panobinostat,Stanozolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Stanozolol undergoes hepatic metabolism. Panobinostat is unlikely to interact with this unspecified metabolic pathway.,See Summary
356,Panobinostat,St John's Wort,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. St Johns wort is a P-gp and CYP3A4 inducer. Concentrations of panobinostat may decrease due to CYP3A4 induction. A decrease in exposure may lead to decreased efficacy. Therefore, coadministration should be avoided.",See Summary
357,Panobinostat,Streptokinase,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Panobinostat is unlikely to interfere with this elimination pathway. However, panobinostat in combination with streptokinase increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
358,Panobinostat,Streptomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is eliminated by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
359,Panobinostat,Sulfadiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest a role of CYP2C9 in sulfadiazine metabolism. Panobinostat does not inhibit or induce CYP2C9.,See Summary
360,Panobinostat,Sulpiride,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Sulpiride is mainly excreted in the urine and faeces as unchanged drug. Panobinostat is unlikely to interfere with this elimination pathway. However, panobinostat and sulpiride may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
361,Panobinostat,Tacrolimus,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tacrolimus is metabolised mainly by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on tacrolimus exposure is not expected in vivo. Tacrolimus is also an inhibitor of CYP3A4 and OATP1B1 in vitro but produced modest inhibition of CYP3A4 and OATP1B1 in the range of clinical concentrations. Therefore, no clinically relevant effect on panobinostat exposure is expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
362,Panobinostat,Tadalafil (Pulmonary Arterial Hypertension),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on tadalafil exposure is not expected in vivo.,See Summary
363,Panobinostat,Tamsulosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) but a clinically relevant effect on tamsulosin exposure is not expected.,See Summary
364,Panobinostat,Tazobactam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is excreted as unchanged drug (approximately 80%) and inactive metabolite (approximately 20%) in the urine. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
365,Panobinostat,Telithromycin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Telithromycin is metabolised by CYP3A4 (50%) with the remaining 50% metabolised via non-CYP mediated pathways. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on telithromycin exposure is not expected in vivo. Telithromycin is also an inhibitor of CYP3A4 (strong) and P-gp. Concentrations of panobinostat may increase due to strong inhibition of CYP3A4. Coadministration of ketoconazole, a strong CYP3A4 and P-gp inhibitor, and panobinostat increased panobinostat AUC and Cmax by 1.6-fold and 1.8-fold, respectively. A similar effect may occur after coadministration with telithromycin. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, reduce the panobinostat starting dose to 10 mg. Monitor closely for panobinostat toxicity. Monitor panobinostat plasma concentrations, if available. If continuous treatment with a strong CYP3A4 inhibitor is required, a dose escalation from 10 mg to 15 mg panobinostat may be considered based on patient tolerability.",See Summary
366,Panobinostat,Telmisartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Panobinostat does not inhibit or induce UGTs.,See Summary
367,Panobinostat,Temazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated. Panobinostat does not inhibit or induce UGTs.,See Summary
368,Panobinostat,Terbinafine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolised by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYP2C8 and CYP2C19. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on terbinafine exposure is not expected in vivo.",See Summary
369,Panobinostat,Testosterone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on testosterone exposure is not expected in vivo.,See Summary
370,Panobinostat,Tetracycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetracycline is eliminated unchanged primarily by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
371,Panobinostat,Theophylline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolised by CYP1A2. Panobinostat does not inhibit or induce CYP1A2.,See Summary
372,Panobinostat,Thiamine (Vitamin B1),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
373,Panobinostat,Thioridazine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but is contraindicated. Thioridazine is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of thioridazine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with thioridazine. Furthermore, the product labels for thioridazine contraindicate its use in the presence of other drugs that prolong the QT interval, such as panobinostat.",See Summary
374,Panobinostat,Tiapride,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Tiapride is excreted largely unchanged in urine. Panobinostat is unlikely to interfere with this elimination pathway. However, panobinostat and tiapride may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
375,Panobinostat,Ticagrelor,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Ticagrelor is a substrate of CYP3A4 and P-gp. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on ticagrelor exposure is not expected in vivo. However, ticagrelor is a weak inhibitor of CYP3A4 and may increase concentrations of panobinostat. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required. Furthermore, panobinostat in combination with ticagrelor increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
376,Panobinostat,Timolol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Timolol is predominantly metabolised in the liver by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of timolol. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with timolol. Therefore, care should be taken if coadministered. Monitoring for timolol toxicity may be required. Note: since the systemic absorption of timolol after ocular administration is low, a clinically relevant interaction is unlikely.",See Summary
377,Panobinostat,Tinzaparin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tinzaparin is renally excreted as unchanged or almost unchanged drug. Panobinostat is unlikely to interfere with this elimination pathway. However, panobinostat in combination with tinzaparin increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
378,Panobinostat,Tolbutamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolised by CYP2C9 and to a lesser extent by CYPs 2C8 and 2C19. Panobinostat does not inhibit or induce CYPs 2C9, 2C8 or 2C19.",See Summary
379,Panobinostat,Tolterodine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Tolterodine is primarily metabolised by CYP2D6 and CYP3A4. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of tolterodine. If coadministration is unavoidable, monitor closely for tolterodine toxicity. Furthermore, panobinostat and tolterodine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
380,Panobinostat,Torasemide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolised mainly by CYP2C9. Panobinostat does not inhibit or induce CYP2C9. Furthermore, OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Panobinostat is an in vitro inhibitor of OAT3. However, no clinically significant effect on torasemide exposure is expected.",See Summary
381,Panobinostat,Tramadol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Tramadol is metabolised by CYPs 3A4, 2B6, and 2D6. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on tramadol exposure is not expected in vivo. Panobinostat is also a weak inhibitor of CYP2D6 and may increase concentrations of tramadol. Therefore, care should be taken when tramadol is coadministered with panobinostat. Monitoring for tramadol toxicity may be required.",See Summary
382,Panobinostat,Trandolapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is hydrolysed to trandolaprilat. Panobinostat does not interact with this metabolic pathway.,See Summary
383,Panobinostat,Tranexamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranexamic acid is mainly cleared by glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway. ,See Summary
384,Panobinostat,Tranylcypromine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranylcypromine is hydroxylated and acetylated. Panobinostat does not interact with this metabolic pathway.,See Summary
385,Panobinostat,Trazodone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Trazodone is primarily metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on trazodone exposure is not expected in vivo. Furthermore, panobinostat and trazodone may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
386,Panobinostat,Triamcinolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on triamcinolone exposure is not expected in vivo.,See Summary
387,Panobinostat,Triazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolised by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on triazolam exposure is not expected in vivo.,See Summary
388,Panobinostat,Trimethoprim/Sulfamethoxazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. To a lesser extent (approximately 30%) trimethoprim is metabolised by CYP-enzymes (in vitro data suggest CYPs 3A4, 1A2 and 2C9). Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on trimethoprim exposure is not expected. Furthermore, trimethoprim is a weak CYP2C8 inhibitor and in vitro data also suggest that trimethoprim is an inhibitor of OCT2 and MATE1. Panobinostat does not interact with this pathway. In addition, sulfamethoxazole is metabolised via and is a weak inhibitor of CYP2C9. Panobinostat does not interact with these pathways.",See Summary
389,Panobinostat,Trimipramine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Trimipramine is metabolised mainly by CYP2D6. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of trimipramine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with trimipramine. Therefore, care should be taken when trimipramine is coadministered with panobinostat. Monitoring for trimipramine toxicity may be required.",See Summary
390,Panobinostat,Tropisetron,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Tropisetron is metabolised mainly by CYP2D6 and is a substrate of P-gp. Panobinostat is a weak inhibitor of CYP2D6 and may increase concentrations of tropisetron. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with tropisetron. Therefore, if coadministration is necessary, monitor closely for tropisetron toxicity. Furthermore, panobinostat and tropisetron may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, monitor ECG.",See Summary
391,Panobinostat,Ulipristal,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ulipristal is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak) but no clinically relevant effect on ulipristal exposure is expected. ,See Summary
392,Panobinostat,Valproic acid (Valproate),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproic acid is primarily metabolised by glucuronidation (50%) and mitochondrial beta-oxidation (30-40%). Panobinostat does not interact with this metabolic pathway. To a lesser extent (10%) valproic acid is metabolised by CYP2C9 and CYP2C19. Panobinostat does not inhibit or induce CYP2C9 or CYP2C19. Valproic acid is also an inhibitor of CYP2C9. Panobinostat is not metabolised by CYP2C9.,See Summary
393,Panobinostat,Valsartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valsartan is eliminated unchanged mostly through biliary excretion. Panobinostat is unlikely to interact with this elimination pathway.,See Summary
394,Panobinostat,Vancomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via glomerular filtration. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
395,Panobinostat,Venlafaxine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Venlafaxine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of venlafaxine. Coadministration of panobinostat and dextromethorphan, a CYP2D6 substrate, increased dextromethorphan AUC and Cmax by 1.64-fold and 1.83-fold, respectively. A similar effect may occur with venlafaxine. Therefore, care should be taken when venlafaxine is coadministered with panobinostat. Monitoring for venlafaxine toxicity may be required.",See Summary
396,Panobinostat,Verapamil,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Verapamil is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8 and 2C9. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on verapamil exposure is not expected in vivo. However, verapamil is a moderate inhibitor of CYP3A4 and may increase concentrations of verapamil. As the clinical relevance of this interaction is unknown, monitoring for panobinostat toxicity may be required.",See Summary
397,Panobinostat,Vildagliptin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vildagliptin is inactivated via non-CYP mediated hydrolysis and is a substrate of P-gp. Panobinostat does not interact with this metabolic pathway.,See Summary
398,Panobinostat,Vitamin E,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
399,Panobinostat,Voriconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Voriconazole is metabolised by CYP2C19 (major) and to a lesser extent by CYP3A4 and CYP2C9. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on voriconazole exposure is not expected in vivo. Voriconazole is also a strong inhibitor of CYP3A4 and a weak inhibitor of CYPs 2C9, 2C19 and 2B6. Concentrations of panobinostat may increase due to strong inhibition of CYP3A4. Coadministration of ketoconazole, a strong CYP3A4 inhibitor, and panobinostat increased panobinostat AUC and Cmax by 1.6-fold and 1.8-fold, respectively. A similar effect may occur after coadministration with voriconazole. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, reduce the panobinostat starting dose to 10 mg. Monitor closely for panobinostat toxicity. Monitor panobinostat plasma concentrations, if available. If continuous treatment with a strong CYP3A4 inhibitor is required, a dose escalation from 10 mg to 15 mg panobinostat may be considered based on patient tolerability.",See Summary
400,Panobinostat,Warfarin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolised by different cytochromes. R-warfarin is primarily metabolised by CYP1A2 and CYP3A4. S-warfarin (more potent) is metabolised by CYP2C9. Panobinostat is inhibitor of CYP3A4 in vitro but a clinically relevant effect on warfarin exposure is not expected in vivo. However, panobinostat in combination with warfarin increases the risk of haemorrhage due to the thrombocytopenic effect of panobinostat. If coadministration is unavoidable, monitor closely for signs of bleeding.",See Summary
401,Panobinostat,Xipamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%). OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Panobinostat is an inhibitor of OAT3 in vitro but a clinically relevant effect on xipamide exposure is not expected in vivo.",See Summary
402,Panobinostat,Zaleplon,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolised by aldehyde oxidase and to a lesser extent by CYP3A4. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on zaleplon exposure is not expected in vivo.,See Summary
403,Panobinostat,Ziprasidone,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but is contraindicated. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on ziprasidone exposure is not expected in vivo. However, the product labels for ziprasidone contraindicate its use in the presence of other drugs that prolong the QT interval, such as panobinostat.",See Summary
404,Panobinostat,Zoledronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zoledronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Panobinostat is unlikely to interfere with this elimination pathway.,See Summary
405,Panobinostat,Zolpidem,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 1A2. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) but a clinically relevant effect on zolpidem exposure is not expected. ",See Summary
406,Panobinostat,Zopiclone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C8. Panobinostat is an inhibitor of CYP3A4 in vitro but a clinically relevant effect on zopiclone exposure is not expected in vivo.,See Summary
407,Panobinostat,Zotepine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Panobinostat is an inhibitor of CYP3A4 (in vitro) and CYP2D6 (weak), but a clinically relevant effect on zotepine exposure is not expected.",See Summary
408,Panobinostat,Zuclopenthixol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Zuclopenthixol is metabolised by sulphoxidation, N-dealkylation (via CYP2D6 and CYP3A4) and glucuronidation. Panobinostat is an inhibitor of CYP2D6 (weak) and CYP3A4 (in vitro) and may increase concentrations of zuclopenthixol. Therefore, coadministration should be approached with caution. If coadministration is necessary, monitor closely for zuclopenthixol toxicity. ",See Summary
